Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MSH2
REST API REST API
Homo sapiens
MSH2 is differentially expressed in 306 experiments: 87 organism parts: liver, thymus, ... (85 more);, 204 disease states: normal, prostate carcinoma, ... (202 more);, 99 cell types 338 cell lines 40 compound treatments and 70 other conditions.
Synonyms COCA1, HNPCC1, HNPCC
Orthologs F1NFH4_CHICK (Gallus gallus)   MSH2 (Saccharomyces cerevisiae)   Msh2 (Rattus norvegicus)   msh2 (Danio rerio)   MSH2_BOVIN (Bos taurus)   Msh2 (Mus musculus)   F6UC46_CIOIN (Ciona intestinalis)   spel1 (Drosophila melanogaster)   msh2 (Xenopus laevis)   Q5SBJ2_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term intra-S DNA damage checkpoint, DNA binding, protein binding, apoptosis, DNA repair, double-stranded DNA binding, damaged DNA binding, ATPase activity, negative regulation of apoptosis, nuclear chromosome, cell cycle arrest, spermatogenesis, male gonad development, MutSalpha complex, single-stranded DNA binding, double-strand break repair, determination of adult lifespan, MutSbeta complex, mismatched DNA binding, meiotic mismatch repair, ATP binding, magnesium ion binding, Y-form DNA binding, DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis, DNA-dependent ATPase activity, protein kinase binding, nucleus, mismatch repair, germ cell development, maintenance of DNA repeat elements, nucleotide binding, response to drug, protein homodimerization activity, four-way junction DNA binding, postreplication repair, protein C-terminus binding, response to DNA damage stimulus, response to X-ray, enzyme binding, negative regulation of neuron apoptosis, guanine/thymine mispair binding, B cell differentiation, MutLalpha complex binding, in utero embryonic development, dinucleotide repeat insertion binding, somatic recombination of immunoglobulin gene segments, ATP catabolic process, ADP binding, dinucleotide insertion or deletion binding, positive regulation of helicase activity, somatic recombination of immunoglobulin genes involved in immune response, response to UV-B, B cell mediated immunity, oxidized purine DNA binding, somatic hypermutation of immunoglobulin genes, centromeric DNA binding, negative regulation of DNA recombination, response to amino acid stimulus, isotype switching, single guanine insertion binding, oxidative phosphorylation, single thymine insertion binding, negative regulation of reciprocal meiotic recombination, loop DNA binding, double-strand/single-strand DNA junction binding, meiotic gene conversion, response to organic cyclic compound
InterPro Term DNA_mismatch_repair_MutS_core, DNA_mismatch_repair_MutS_clamp, DNA_mismatch_repair_MutS-lik_N, DNA_mismatch_repair_MutS_connt, DNA_mismatch_repair_MutS_C, DNA_mismatch_repair_MSH2
UniProt Accession Q53RU4, C9J809, P43246, B4DSB9, B4E2Z2, B4DL39, E7EQQ1, E7EU21, E9PCI8, E9PHA6
Gene-Disease Assocation CAFE-AU-LAIT SPOTS, MULTIPLE, LYNCH SYNDROME I, ENDOMETRIAL CANCER, MISMATCH REPAIR CANCER SYNDROME, GLIOMA SUSCEPTIBILITY 1; GLM1, NEUROFIBROMATOSIS, TYPE I; NF1, COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 8; HNPCC8, MUIR-TORRE SYNDROME; MRTES
Search EB-eye ENSG00000095002
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MTAB-24, E-MEXP-433, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (40 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
PC3
3
E-MEXP-2034, E-GEOD-14464, E-GEOD-5258
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
Jurkat
2
E-GEOD-1880, E-MTAB-62
MDA468
2
E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
332 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, E-GEOD-13909, ... (47 experiments)

Factor Value U/D Experiments
testis - germ cell
2
E-AFMX-5, E-TABM-145
adipocyte
2
E-AFMX-5, E-TABM-145
2
E-TABM-145, E-TABM-130
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
memory B cell
2
E-MEXP-2360, E-TABM-702
93 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-4060, ... (58 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-96
acute lymphoblastic leukemia
2
E-MTAB-37, E-GEOD-96
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
colorectal adenocarcinoma
2
E-MTAB-62, E-MTAB-37
198 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-4668, E-GEOD-1417, E-TABM-782, E-GEOD-3720, ... (27 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-GEOD-3720, E-TABM-868, E-MEXP-1958
mercaptopurine, methotrexate
1
E-GEOD-412
sevoflurane
1
E-GEOD-4386
unknown
1
E-GEOD-7307
control
1
E-GEOD-995
endotoxin
1
E-GEOD-3026
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-1725, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-1140, E-GEOD-2034, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, ... (6 experiments)

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-MEXP-2280, ... (9 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (11 experiments)

Genotype
studied in E-GEOD-1923, E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-GEOD-20504, E-MEXP-1446, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-GEOD-2466, E-MEXP-2069, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-980, E-GEOD-360 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-1493, E-GEOD-21750, E-GEOD-1657, ... (8 experiments)

Population
studied in E-MTAB-197, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837

RNAi
studied in E-GEOD-1703, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7540, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.333 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM